| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CFHL2 |
| Uniprot No | P36980 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-270aa |
| 氨基酸序列 | EA MFCDFPKINH GILYDEEKYK PFSQVPTGEV FYYSCEYNFV SPSKSFWTRI TCAEEGWSPT PKCLRLCFFP FVENGHSESS GQTHLEGDTV QIICNTGYRL QNNENNISCV ERGWSTPPKC RSTISAEKCG PPPPIDNGDI TSFLLSVYAP GSSVEYQCQN LYQLEGNNQI TCRNGQWSEP PKCLDPCVIS QEIMEKYNIK LKWTNQQKLY SRTGDIVEFV CKSGYHPTKS HSFRAMCQNG KLVYPSCEEK |
| 分子量 | 30.6 KDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人补体因子H相关蛋白2(CFHL2)的3-4篇模拟参考文献，内容基于补体相关研究的典型方向：
1. **文献名称**：*"Functional Characterization of CFHL2 as a Complement Regulatory Protein in Alternative Pathway Inhibition"*
**作者**：Rodríguez de Córdoba S, et al.
**摘要**：本研究首次报道了重组人CFHL2蛋白的克隆与功能分析，揭示其通过竞争性结合C3b抑制补体旁路途径的过度激活，证实其与CFH相似的调控机制，但具有组织特异性表达模式。
2. **文献名称**：*"CFHL2 Genetic Variants Associate with Age-Related Macular Degeneration in a European Cohort"*
**作者**：Zipfel PF, Skerka C, et al.
**摘要**：通过全基因组关联分析，发现CFHL2基因多态性与年龄相关性黄斑变性(AMD)风险显著相关。体外实验表明，突变型重组CFHL2蛋白结合C反应蛋白能力下降，导致补体炎症反应失控。
3. **文献名称**：*"Structural Basis of CFHL2 Interaction with C3d: Insights from X-ray Crystallography"*
**作者**：Jokiranta TS, et al.
**摘要**：利用X射线晶体学解析了CFHL2与补体片段C3d的复合物结构，揭示了其短共有重复(SCR)结构域的关键结合位点，为设计靶向CFHL2的补体抑制剂提供了分子基础。
4. **文献名称**：*"CFHL2 Deficiency Exacerbates Renal Injury in a Mouse Model of Thrombotic Microangiopathy"*
**作者**：Pickering MC, et al.
**摘要**：构建CFHL2基因敲除小鼠模型，发现其在补体激活刺激下肾小球损伤加剧，表明CFHL2在保护内皮细胞免受补体介导的血栓性微血管病中起关键作用。
---
**注**：以上文献为学术模拟，实际研究需通过数据库(如PubMed)检索关键词“CFHL2”或“CFHR2”(部分文献中CFHL2也被称为CFHR2)。建议结合具体研究方向筛选近年高被引论文。
Complement factor H-related protein 2 (CFHL2), a member of the factor H protein family, plays a critical role in regulating the complement system, a key component of innate immunity. Encoded by the *CFHL2* gene, this protein shares structural homology with complement factor H (CFH), containing conserved short consensus repeat (SCR) domains. It is primarily involved in fine-tuning the alternative complement pathway by binding to C3b and facilitating its inactivation, thereby preventing excessive complement activation on host tissues. This regulatory function helps protect healthy cells from unintended immune-mediated damage while enabling targeted pathogen clearance.
Dysregulation of CFHL2 has been linked to several pathologies. Genetic variations or deficiencies may contribute to renal diseases, age-related macular degeneration (AMD), and thrombotic microangiopathies, often through impaired control of complement-driven inflammation. Its interaction with CFH and other regulatory proteins adds complexity to complement pathway modulation, making it a subject of interest in autoimmune and inflammatory disorders.
Recombinant CFHL2 protein, typically produced in mammalian expression systems, retains functional domains necessary for immune regulation. Researchers utilize it to dissect complement activation mechanisms, develop therapeutic inhibitors for complement-mediated diseases, and explore diagnostic biomarkers. Recent studies also investigate its potential in managing conditions like atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathies. As complement-targeted therapies gain momentum, CFHL2 remains a focal point for understanding immune homeostasis and developing precision medicine approaches.
×
